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Abstract
Objectives The aim of the present study is to analyze preclinical and clinical data on the performance of the currently US Food
and Drug Administration (FDA)–approved microwave ablation (MWA) systems.
Methods A review of the literature, published between January 1, 2005, and December 31, 2016, on seven FDA-approvedMWA
systems, was conducted. Ratio of ablation zone volume to applied energy R(AZ:E) and sphericity indices were calculated for
ex vivo and in vivo experiments.
Results Thirty-four studies with ex vivo, in vivo, and clinical data were summarized. In total, 14 studies reporting data on
ablation zone volume and applied energy were included for comparison R(AZ:E). A significant correlation between volume
and energy was found for the ex vivo experiments (r = 0.85, p < 0.001) in contrast to the in vivo experiments (r = 0.54, p = 0.27).
Conclusion Manufacturers’ algorithms on microwave ablation zone sizes are based on preclinical animal experiments with
normal liver parenchyma. Clinical data reporting on ablation zone volume in relation to applied energy and sphericity index
during MWA are scarce and require more adequate reporting of MWA data.
Key Points
• Clinical data reporting on the ablation zone volume in relation to applied energy during microwave ablation are scarce.
• Manufacturers’ algorithms on microwave ablation zone sizes are based on preclinical animal experiments with normal liver
parenchyma.
• Preclinical data do not predict actual clinical ablation zone volumes in patients with liver tumors.
Keywords Microwaves . Ablation techniques . Electromagnetic radiation . Tumor volume . Liver diseases
Abbreviations
ASR Ablation site recurrences
CRLM Colorectal liver metastases








Thermal ablation such as microwave ablation (MWA) is wide-
ly applied for the treatment of liver tumors. Thermal ablation
alone or in combination with partial hepatectomy increases the
number of intentionally curative treatments in patients in
whom partial hepatectomy alone is not an option because of
anatomical or functional reasons. Especially in patients with
recurrent colorectal liver metastases (CRLM) after previous
partial hepatectomy, thermal ablation increases the number
of patients who could benefit from repeated procedures [1,
2]. However, the major problem of thermal ablation is incom-
plete ablation leading to ablation site recurrences (ASR), for
which a clear definition should be used [3]. ASR is shown in
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60% of patients with a lesion > 5 cm compared to 26% for 3–
5 cm lesions and 16% for lesions < 3 cm [4].
Shape and volume of the ablation zone after MWA are
depending on physical parameters as thermal conductivity,
perfusion rate of the liver parenchyma. These parameters can
be different in human liver tissue due to fibrosis, cirrhosis or
steatosis [5, 6]. Planning for ablation is partially based on
manufacturer-initiated working algorithms in combination
with personal experience of the operator. These algorithms,
which try to predict the three-dimensional diameter of the
ablation zone in relation to the amount of applied energy, are
often based on experiments which have serious shortcomings
preventing a reliable translation to daily clinical practice.
These shortcomings are the result of studies performed in (a)
porcine or bovine liver (as opposed to human liver), (b) liver
parenchyma (as opposed to tumors), (c) normal liver paren-
chyma (as opposed to cirrhotic, steatosis, or otherwise non-
normal liver parenchyma in humans), and (d) non-perfused
ex vivo livers (as opposed to perfused in vivo human livers
with variable arterial and portal blood flow). These differences
affect the way in which the applied energy is transferred into
heat, resulting in highly unpredictable ablation zone vol-
umes [6]. Additionally, despite several individual papers
reporting on these shortcomings, a systematic review on
this topic is lacking. The aim of this review is to analyze
preclinical and clinical data on the performance of the US
Food and Drug Administration (FDA)–approved MWA
systems. [7]
Methods
Literature search and collected data
A systematic review of seven FDA-approved microwave ab-
lation systems was performed in accordance with the
PRISMA statement (Table 1) [13]. Literature published be-
tween 1 January 2005 and 1 January 2017, was searched on
Scopus including MEDLINE and EMBASE database, using
the keywords Bmicrowave ablation^ AND Bliver.^ Retrieved
studies were assessed for eligibility based on title and ab-
stract—full papers were obtained and assessed in detail.
Studies were included if (a) data on diameter or volume of
the ablation zone—based on imaging or pathology—was re-
ported, (b) ablation procedures were performed with FDA-
approved MWA systems (Table 1), and (c) the amount of
applied energy was reported and (d) were published in
English. A data extraction form was used to collect relevant
information including type of study (ex vivo, in vivo, or clin-
ical), subject (porcine, bovine, sheep, or human), malignancy
(none, primary, or secondary), device, parameters/outcomes,
and measurement of ablation zone dimensions (on imaging or




























































































































































































































































































































































































































literature was performed by one researcher. Equivocal papers
or data were discussed with co-authors until consensus was
obtained. The included studies were categorized in preclinical
(animal) and clinical (patient) studies. Preclinical studies were
subdivided in two subcategories: ex vivo and in vivo studies
(Table 1).
Ablation zone volume and applied energy
Ablation zone volume as reported in the selected papers was
recorded. If only long-axis diameter (LAD) and short-axis di-
ameters (SAD) were recorded, the ablation zone volume was
estimated, assuming ellipsoid morphology by V ¼ 43π
LAD=2ð Þ SAD=2ð Þ2. Papers with only one diameter of the
ablation zone were excluded for quantitative comparison.
Sphericity index of ablation zones with reported SAD and
LAD was calculated by SI = SAD2/LAD2.
The cumulative applied energy was determined by multi-
plying the power level (Watt), as set on the MWA generator,
and the ablation time (seconds). The relation between applied
energy and ablation zone volume is the only way to quantita-
tively compare the various published reports. To this end, the
ratio of ablation zone volume to applied energy R(AZ:E) of
each ablation experiment was calculated by dividing the abla-
tion zone volume (mL) by the applied energy (kJ). The corre-
lation coefficient was determined using IBM SPSS Statistics
version 23 (IBM Corporation). The mean volume and applied
energy of the subgroups were represented in a bubble chart.
The sizes of the bubbles are determined by the sample size of
the subgroup.
Results
Figure 1 shows a flow diagram of study identification
and the exclusion process, resulting in 34 eligible studies
[8–12, 14–42] (Tables 2, 3, and 4). Cross-referencing of
the identified studies did not reveal any additional papers.
In three studies, both ex vivo and in vivo data were
published [8–10], and these were counted as six separate
studies in Table 1. In one study, ex vivo, in vivo, and
clinical data were presented [11], and these were counted
as three separate studies. Also, in one paper, the ex vivo
data of four MWA devices were presented, and these
were counted as four separate studies [12]. Assessment
of publication bias (overreporting of significant positive
results) is not applicable for this review, because the data
is not presented as negative or positive. We performed a
partial correction for the heterogeneity (variability in the
study characteristics) in the analyzed studies by reporting
stratified results (for instance ex vivo vs. in vivo and
animal vs. human).
Ex vivo animal studies
In total, 18 studies published ex vivo animal results, three in
porcine liver [23, 30, 39] and 15 in bovine liver (Table 1)
[8–12, 17, 20, 22, 24, 25, 33, 35, 37, 38, 41]. Four studies
were performed in perfused liver [25, 30, 37, 38]. Dodd et al
used 15 blood-perfused (37 °C) bovine livers for 60 MWabla-
tions with system G (MicroThermX) [37]. Ablation zone vol-
umes, measured by gross pathology, were unaffected by chang-
es in portal venous blood flow (range of 60–100 mL/min
per 100 g tissue). These authors also repeated the blood-
perfused study with 60 ablations in ten livers with system C
(NeuWave) [38]. Again, a change in blood flow rate did not
affect the size and shape of the ablation zone, as evaluated by
pathology. Pillai et al perfused ex vivo bovine livers with
37 °C Ringer solution and compared volumes and diameters
of ablation zones in relation to the distance to the major hepatic
vein in three ablation experiments [25]. For system D
(AveCure), ablation zones within 8 mm to the major hepatic
veins were 22% smaller than ablation zones more than 30 mm
away from major hepatic veins [25]. Ringe et al used perfused
glass tubes in porcine liver to simulate the hepatic veins [30].
They analyzed 108 ablation zones generated by system E
(Evident) and found that ablation zones were influenced by
flow rate (0, 700, and 1400 mL/min) at a maximum distance
of 10 mm to the glass tube. Hoffmann et al compared the four
systems A, B, D, and E (Acculis, Amica, AveCure, and


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(NeuWave, 3 antennas) created the largest and most spherical
zones. Most systems note in their manual that ablation algo-
rithms are based on Binternal ex-vivo experiments.^ However,
no peer-reviewed publications were found for ex vivo testing
for system F (Emprint).
In vivo animal studies
In 12 animal studies, the effects of microwave ablation in
in vivo liver parenchyma were analyzed [8–11, 14, 15, 18,
19, 26–28, 34]. Gockner et al compared MWA using system
A (Acculis) with and without transarterial embolization before
ablation in sheep [19]. Extent and shape of the ablation zones
were determined by CT. Ablation zone diameters increased by
22.8% by using transarterial embolization before ablation
(p < 0.01). Hines-Peralta et al compared ex vivo bovine and
in vivo porcine MWA, using system A (Acculis) [9].
Unexpectedly, 8-mm larger (57 mm vs. 49 mm) diameter of
ablation zones (p < 0.01) were obtained in in vivo (57 ± 2mm)
experiments, compared to ex vivo (49 ± 2 mm). However, for
ablation times longer than 8 min, ex vivo diameters still in-
creased while in vivo diameters remained constant. Also,
Lubner et al compared ex vivo bovine and in vivo porcine
MWA [10]. Ablation zones were similar during the first
2 min, but in vivo ablations did not continue to grow as much
as ex vivo [10]. No in vivo studies were performed with sys-
tem D (AveCure) and system F (Emprint).
Clinical studies
Nine studies reported clinical results of the ablation zone [11,
16, 18, 29, 31, 32, 36, 40, 42]. Ratanaprasatporn et al per-
formed a prospective study in ten patients with liver tumors,
treated with system D (AveCure) [40]. After liver resection,
the ablation zone volumes were measured on gross pathology.
Six of the ten treatments showed ablation with complete ne-
crosis on pathological examination [40]. Di Vece et al reported
a mean long-axis diameter of 4.85 cm in 20 patients treated
with system B (Amica) [42]. Winokur et al analyzed the ab-
lation properties of system B (Amica, 25 ablations in 20 pa-
tients) and system C (NeuWave, 11 ablations in 8 patients) in
order to analyze if the manufacturer published reference
values are useful [16]. The study indicated that in vivo
(clinical) ablation zone volumes are significantly smaller than
stated by reference values from the manufacturers (0.69 cm3
vs. 1.29 cm3; p = 0.003) [16]. Berber et al compared predicted
ablation diameters (system F, Emprint) with the ablation zone
at the 2-week post-ablation CT scan of nine patients [29]. The
maximum diameter of the ablation zone was 1.12 ± 0.11 times
larger than predicted. No residual tumors were seen at the 2-
week scan. In another study, Berber reported a scatterplot
showing the CT diameter of ablation zones obtained after
100 W of power during laparoscopic MW ablation with
system F (Emprint) in 15 patients [31]. In a study of 149
laparoscopic ablations, Zaidi et al reported system F to be
satisfactory in achieving the predicted ablation sizes [32].
Amabile et al compared ablation zone dimensions in liver
tumors in patients with both in vivo (porcine) and ex vivo
(bovine) experiments (only liver parenchyma). They conclud-
ed that the ex vivo animal data reliably predicted the dimen-
sions in (in vivo) human liver tumors. Shyn et al compared
ablation zone diameters and volumes with applied and net
energy (after correcting for reflectivity), and with manufactur-
er chart predictions [36]. Applied energy (r = 0.52) and net
energy (r = 0.53) did not correlate better than manufacturer
chart prediction (r = 0.60). Also, no differences were seen be-
tween cirrhotic and non-cirrhotic livers. None of the clinical
studies were performed with system A (Acculis), E (Evident),
and G (MicroThermX).
Comparison of ablation volume–applied energy ratio
In total, 14 animal studies reported data on ablation zone vol-
ume and applied energy and could be used to compare
R(AZ:E) [8, 9, 11, 12, 14, 17, 19, 22–24, 26, 30, 35, 39].
These studies were categorized in 22 subgroups based on
device and tissue (ex vivo and in vivo). A significant correla-
tion between volume and energy was found for the ex vivo
experiments (r = 0.85, p < 0.001) in contrast to the in vivo
experiments (r = 0.54, p = 0.27) (Fig. 2). Results of SI calcu-
lation are shown in Tables 2, 3, and 4.
Discussion
In this review on studies performedwith seven FDA-approved
MWA devices, we found that only a minority (9 out of 43
studies) was based on clinical studies. On top of that, a major
limitation in these clinical studies is the lack of data on the
ratio ablation zone volume: applied energy R(AZ:E). In only
14 preclinical studies, the R(AZ:E) was calculated. To our
knowledge, this is the first study which compares the ratio
ablation zone volume and applied energy of FDA-approved
MWA devices between 2005 and 2017. MWA systems are
categorized as class II medical devices by the FDA. This clas-
sification requires that a new device must be proven to be
substantially equivalent to a device that was legally marketed
(predicate device) prior to May 28, 1976. Since microwave
technology has been around for decades, ex vivo bench testing
is sufficient for the regulatory approvals and no additional
submission of clinical data is required [7]. Also, reporting
results on ablation zone volume and applied energy in clinical
setting are limited. This might be the reason for the lack of
clinical data of MWA systems.
An analysis of the studies in our review suggests a number









































































































































































































































































































































































































































































































































































































































































































































































































































































































manufacturers’ provided ablation algorithms and the actual
clinical ablation zone sizes. This discrepancy was demonstrat-
ed by Winokur et al who indicated that in vivo (clinical) ab-
lation zone volumes are significantly smaller than stated by
reference values from the manufacturers of the Amica and
NeuWave system [16]. Depending on the type of study
(ex vivo vs. in vivo), ablation time was found to be a determi-
nant for ablation zone diameter. For ablation time longer than
8 min, ex vivo diameter still increased while in vivo diameters
remained constant, suggesting plateau formation which prob-
ably is caused by the antagonizing effect of perfusion [9, 16].
Obviously, preclinical studies using animal livers are only
performed in normal liver parenchyma with absence of tumor
tissue (tumor characteristics) and underlying liver disease (liv-
er characteristics). Deshazer et al simulated these properties in
a two-compartmental computer model and showed that abla-
tion zone volume could increase with 36% in patients with
cirrhotic liver as compared to healthy liver tissue [6]. Tumor
tissue revealed a 20% higher thermal conductivity (the prop-
erty of tissue to conduct heat) than healthy liver tissue.
Hyperperfused and hypoperfused tumors within normal liver
parenchyma showed minimal variation in ablation zone vol-
ume. Furthermore, steatotic parenchyma had 50% lower ther-
mal conductivity than healthy liver tissue [6]. Hepatic
steatosis is of importance in patients with CRLM treated with
neo-adjuvant chemotherapy and should be taken into account
when planning MWA treatment for these patients [43].
Perfusion in ex vivo experiments also determines to a great
extent the effect of heat distribution by convection in MWA;
convection of heat is mainly influenced by vascularization of
the tumor and adjacent large blood vessels which can cause
heat sink. In most ex vivo studies, livers were not perfused and
thus not subject to heat sink effects. Perfusion of cirrhotic liver
tissue is reported to be 36% lower than healthy liver tissue
[44]. This is of importance because approximately 90% of the
patients with HCC suffer from cirrhosis [45]. Additionally, the
majority of HCCs have a predominant arterial perfusion,
which makes prediction of the obtained ablation zone in rela-
tion to perfusion phenomena even more imprecise. Compared
to perfusion in liver parenchyma, HCC tumor tissue has a
significantly higher arterial perfusion and lower portal venous
hepatic blood flow [46]. Therefore, the results of Amabile et al
are difficult to interpret, because they found a better correla-
tion between ablation zone dimensions in liver tumors (HCC)
in patients and non-perfused (ex vivo) bovine liver than in
perfused (in vivo) porcine liver. A possible explanation for
this seemingly contradictory finding is that less than 20% of
the ablation zone volume encompasses tumor and more than
80% liver parenchyma [47]. This suggests that liver parenchy-
ma might be of more importance for the ablation zone volume
than the tumor tissue. Clinical studies were limited in number
and additionally in general no distinction in tumor type (pri-


























































































































































































































































































































































































































































































































































































































































































































































reported the underlying liver diseases, like hepatic steatosis,
fibrosis, or cirrhosis. In a retrospective study, MWA volumes
of HCC in cirrhotic liver and CRLM in healthy liver were
compared. R(AZ:E) for HCC with system A (Acculis) is two-
fold higher for HCC (R(AZ:E) = 0.61) compared to CRLM
(R(AZ:E) = 0.35). Also, ablation treatment for HCC with sys-
tem B (Amica) resulted in a 50% increase of ablation zone
volume, compared to CRLM [47]. For treatment of HCC up to
4 cm, no significant differences were found in local tumor
progression between radiofrequency ablation (RFA) and
MWA [48].
During liver ablation, the power of heating (Watt) is an
important factor. When using low power, relatively more heat
will be dispersed into the surrounding tissue, and temperature
of the ablation zone will be low. In contrast, higher power for
short time will lead to high temperatures around the antenna
and contraction of the target tissue. Bedoya et al compared
different ways to deliver 30 kJ of energy (25 W 20 min,
50 W 10 min, and 100 W 5 min) in in vivo porcine livers
[27]. Significantly larger ablation zone volumes were
achieved with high power ablations (23.6 ± 26.5 mL; 105.4
± 78.3 mL; 265.7 ± 208.1, respectively; p < 0.03).
Interestingly, they also investigated the effect of pulsed energy
delivery (25 kJ) to limit the effects of heat sink and to provide
larger ablation zone volumes than continuous energy delivery
(67.4 ± 34.5 cm3 vs. 23.6 ± 26.5 cm3, p = 0.43).
Another important factor is the reflection of energy by the
antenna cable. The majority of the microwave systems report
the output power of the generator as the applied energy at the
antenna. However, 15–30% of the output energy per meter
length will be lost by the antenna cable [49]. So, for compar-
ison of ablation devices by R(AZ:E), the most relevant param-
eter is the amount of energy deposited into the liver tissue,
which is known as the net energy [5, 49, 50]. Only systems B
(Amica) and D (AveCure) display the reflection of energy on
the generator. A comparable disagreement is found for the
various antenna designs: if an antenna is built to have stronger
fields in certain areas (Watts/area), a different amount of tissue
reaching 60 °Cmight be expected. So, differences in R(AZ:E)
between devices might be due to antenna design and cable
length [49]. Despite the limitation of using R(AZ:E), it is the
only parameter to compare the currently available data
quantitatively.
Most liver tumors treated by MWA are spherical which
requires also a spherical ablation zone to achieve a sufficient
ablation margin. However, most ablation systems create ellip-
soidal ablation zones with poor sphericity values. Reflection
of energy by the antenna shaft results in heating of the shaft
which contributes to bigger LAD. This may also increase the
risk of thermal damage of adjacent liver tissue. Data about the
sphericity of ablation zones in patients are scarce. In this study,
we calculated the SI for all studies in which the LAD and SAD
were reported. However, data are heterogeneous and depend-
ing on power and time of the ablation. A recently published
Fig. 2 Bubble chart of the ratio of
ablation zone volume (mL) to
applied energy (kJ) R(AZ:E) for
22 subgroups in animal studies of
all devices with adequate volume/
energy representation. The sizes
of the bubbles are determined by
the sample size of the subgroup
Table 5 Guidelines for reporting on future studies describing ablation
experiments
Variable Value
Type of experiments Ex vivo (perfused, non-perfused),
in vivo, clinical
Subjects animal (porcine, bovine), human
Type of liver parenchyma normal, cirrhosis, fibrosis, steatotic
Device
Applied energy (kJ) Energy = ablation time (seconds) ×
power (Watt) / 1000
Ablation diameters (cm) Long-axis diameter (LAD) and
short-axis diameter (SAD)
Ablation zone volume (mL) V ¼ 43π LAD=2ð Þ SAD=2ð Þ 2
Sphericity index SI = SAD2/LAD2
LAD long-axis diameter, SAD short-axis diameter
Eur Radiol
study compared system F (Emprint) with systems B (Amica)
and E (Evident) [51]. Significantly more spherical ablation
zones in patients were achieved with system F than with sys-
tems B and E. Complete ablation was possible with a single
antenna placement regardless of the angle approach because
of the almost spherical ablation zone.
There might be several strategies to decrease ASR after
microwave ablation. First of all, more in vivo and clinical
studies with MWA should be conducted with cirrhotic and
other diseased parenchyma, like steatotic liver, to confirm
computer model studies. Secondly, presentation of data in
studies should be reported adequately by means of applied
energy (without reflection), LAD, SAD, SI, and volume of
each ablation zone (Table 5). Additionally, for clinical studies,
the status of the underlying liver parenchyma should be
reported.
There are some limitations to this study. Ablation out-
comes were compared by R(AZ:E). Ablation zone volume
as reported in the selected papers was recorded. If only
one or two diameters were reported, the ablation zone
volume was estimated assuming ellipsoid or spherical
morphology. Also, the diameters or volumes of the abla-
tion zones were assessed by different measurement mo-
dalities (gross pathology, CT, MRI, or ultrasound) which
induce bias. Finally, a systematic review formally requires
a control group, but it is clear that this is not available for
the current review.
In conclusion, manufacturers’ algorithms on microwave
ablation zone sizes are based on preclinical animal experi-
ments with normal liver parenchyma. Clinical data reporting
on ablation zone volume in relation to applied energy and
sphericity index during MWA are scarce which requires more
adequate reporting on MWA data.
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